Kymera Therapeutics Inc (NAS:KYMR)
$ 47.74 0.89 (1.9%) Market Cap: 3.09 Bil Enterprise Value: 2.57 Bil PE Ratio: 0 PB Ratio: 3.46 GF Score: 50/100

Q3 2022 Kymera Therapeutics Inc Earnings Call Transcript

Nov 03, 2022 / 12:30PM GMT
Release Date Price: $30.92 (+7.55%)
Operator;Nello Mainolfi
Kymera

Good morning. My name is Mandeep, and I'll be your conference operator today. Welcome to the Kymera Therapeutics quarterly conference call. Leading the call from management are Nello Mainolfi, Founder and CEO; Jared Gollob, Chief Medical Officer; and Bruce Jacobs, Chief Financial Officer. (Operator Instructions)

Before we get started, I would like to remind everyone that some of the comments that management make on this call include forward-looking statements as outlined in the press release. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in Kymera's most recent filings with the SEC and any other future filings that the company may make with the SEC. You are cautioned not to place any undue reliance on these forward-looking statements, and Kymera disclaims any obligation to update such statements.

I will now hand the call to Nello Mainolfi, Founder, President and CEO.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot